Pharmaceutical company Galderma has revealed results from its two phase IIIb trials investigating relabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines.
The first phase IIIb, randomised, double-blind, placebo-controlled trial assessed the aesthetic improvement and onset of action of relabotulinumtoxinA in patients with moderate to severe frown lines. The trial met its endpoint, with 92.9% of those treated rating their frown lines as ‘improved’ or better on the Global Aesthetic Improvement Scale (GAIS) at month one, compared to 9.1% of those treated with placebo.
The second phase IIIb, open-label, single-centre study to assess aesthetic improvement of relabotulinumtoxinA in patients with moderate to severe crow’s feet and frown lines. It also met its primary endpoint, with 100% of patients treated rating their crow’s feet and frown lines as ‘improved’ or better on the GAIS at month one, according to Galderma. Baldo Scassellati Sforzolini, global head of research and development at Galderma, said, “These results provide an additional layer of confidence in the long-lasting efficacy, speed and convenience of relabotulinumtoxinA, which not only represents the innovation of our neuromodulator portfolio, but also demonstrates our commitment to responding to the real needs of healthcare professionals and patients.”
